Australian families are grappling with a significant shortage of Concerta, a medication widely used to treat attention-deficit/hyperactivity disorder (ADHD). The situation is dire, with some families struggling to function without this essential drug, as expressed by Ruth, a mother of three who only discovered she had ADHD while completing a questionnaire for her children.
Approximately one in 20 Australians is diagnosed with ADHD, and the recent surge in diagnoses has exacerbated the global supply of Concerta. The shortage has led to desperate families resorting to hoarding leftover medication to get by, as Ruth reveals that her family has been stockpiling what remains.
The manufacturer, Johnson & Johnson, announced that a shipment originally scheduled for May has been postponed until December, leading to heightened anxiety among those dependent on the medication. Meanwhile, 17-year-old Kai shared how life without Concerta feels chaotic, impacting his ability to cope effectively.
The Therapeutic Goods Administration (TGA) has acknowledged the shortages, attributing it to manufacturing issues and an unexpected rise in demand. The TGA is facilitating access to overseas alternatives for some methylphenidate products, although these alternatives are not subsidised under the Pharmaceutical Benefits Scheme (PBS).
As the situation unfolds, patients are urged to consult healthcare professionals for guidance and potential solutions. The ongoing shortage reflects a complex interplay of increased ADHD diagnoses and supply chain issues, leaving many families in distress as they navigate the challenges posed by the unavailability of this critical medication.